Latest Breaking News On - ப்ரொஃபெஸர் மைக்கேல் மகிழ்ச்சி - Page 1 : vimarsana.com
Kadimastem Patent for cell selection of beta cells to Treat and Potentially Cure Diabetes was Granted in Japan
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Investegate |Kadimastem Ltd Announcements | Kadimastem Ltd: Kadimastem Patent for cell selection of beta cells to Treat and Potentially Cure Diabetes was Granted in Japan
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Kadimastem Granted a Patent in Israel for the Directed Differentiation of Astrocytes from Human Pluripotent Stem Cells (AstroRx®) for use in Drug Screening and the Treatment of ALS
USA - English
Share this article
NESS ZIONA, Israel, March 9, 2021 /PRNewswire/
Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, announced that it has been granted a patent by The Israel Patent Office for its differentiated human astrocytes from human pluripotent stem cells for use in the treatment and drug screening of Amyotrophic Lateral Sclerosis (ALS).
Specifically, the patent allows for the innovative method of non-genetically modifying a cell population of human progenitor astrocytes or astrocytes, for use in the treatment or prevention of the progression of ALS in a human subject in need and screening an agent for preventing or treating Amyotrophic Lateral Sclerosis (ALS) by using this cell population.
Kadimastem Granted a Patent in Israel for the Directed Differentiation of Astrocytes from Human Pluripotent Stem Cells (AstroRx®) for use in Drug Screening and the Treatment of ALS
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Kadimastem hopes to turn corner with new management
The Israeli stem cell technology company has named Asaf Shiloni CEO, after three new expert directors joined its board.
Israeli stem cell technology company Kadimastem (TASE: KDST) has had a chequered history, with frequent going concern warnings on its financials, a downward drifting share price from its 2016 peak, and the departure last year of founder and CEO Yossi Ben-Yosef. The company now hopes to have turned a corner with the appointment of a new and experienced CEO and new directors.
Kadimastem has named Asaf Shiloni, who was Vice President of Sales and Business Development at California-based PeproTech Inc., as CEO. PeproTech is the leading manufacturer of GMP Cytokines, vital components in all stem cell and cell therapy clinical trials. Kadimastem s announcement states that at PeproTech Shiloni established collaborations and joint ventures with top US stem cell companies and leading research labs worldwide, and also led